Provention Bio, Inc. recently announced top-line results with its drug candidate PRV-300 for the treatment of ulcerative colitis.
The Phase Ib PHASE clinical trial, which included 37 patients at three sites, met its primary safety and tolerability endpoints. An analysis of this trial and all other ulcerative colitis trials can be found in the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. In this article, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
Go deeper with GlobalData
Looking back at clinical trials that started in the last five years, 2016 had the most clinical trials, with about 22.4%, followed by 2018 (20.6%) and 2017 (19.6%) (Figure 1). Breaking down these trials further by trial status shows that the majority of trials have been completed, followed by ongoing, recruiting and suspended/terminated/withdrawn (S/T/W) (Figure 2).
Phase II clinical trials make up almost half of all clinical trials in the Clinical Trials Database, at 42.8%, followed by Phase I, Phase IV, Phase III, and Phase O (Figure 3). Breaking down trials by single country versus multinational, single country outnumbers multinational in all trial phases (Figure 4).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Provention Bio Inc